JD Esq - Curative Biotechnology CFO, CEO

All Insiders . USA . 
Stock . Curative Biotechnology . Stakeholders . Insider . JD Esq
CUBT Stock  USD 0.01  0  14.71%   

Insider

JD Esq is CFO, CEO of Curative Biotechnology
Age 72
Address 3801 PGA Blvd, Palm Beach Gardens, FL, United States, 33410
Phone561 907 8990
Webhttps://curativebiotech.com

Curative Biotechnology Management Efficiency

The company has return on total asset (ROA) of (0.5178) % which means that it has lost $0.5178 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.9828) %, meaning that it created substantial loss on money invested by shareholders. Curative Biotechnology's management efficiency ratios could be used to measure how well Curative Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Curative Biotechnology's Return On Capital Employed is comparatively stable compared to the past year. Return On Equity is likely to gain to 1.75 in 2025, despite the fact that Return On Tangible Assets are likely to grow to (4.21). Total Current Liabilities is likely to gain to about 6.9 M in 2025. Liabilities And Stockholders Equity is likely to gain to about 3.1 M in 2025
Curative Biotechnology currently holds 2.26 M in liabilities with Debt to Equity (D/E) ratio of 6.6, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Curative Biotechnology has a current ratio of 0.1, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Curative Biotechnology's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Steven KingMosaic Immunoengineering
59
Paul CPAMosaic Immunoengineering
55
Gerry ArambulaCovalon Technologies
N/A
Jean EpinatCellectis SA
N/A
Hamed AbbasianCovalon Technologies
N/A
Greg LeszczynskiCovalon Technologies
N/A
Nicole SteinmetzMosaic Immunoengineering
43
Simon SmithCovalon Technologies
N/A
Dr MBACellectis SA
46
Marvin MDMosaic Immunoengineering
79
Jay CarlsonMosaic Immunoengineering
N/A
Ron HebertCovalon Technologies
N/A
Pascalyne WilsonCellectis SA
N/A
Joseph MPHMosaic Immunoengineering
50
Jason GorelCovalon Technologies
N/A
Kyung NamWortmanCellectis SA
53
Elaine ZhangCovalon Technologies
N/A
Mark DoolittleCovalon Technologies
N/A
Valerie CrosCellectis SA
N/A
MSc MScCellectis SA
54
Cyril EmpigMosaic Immunoengineering
N/A
Curative Biotechnology, Inc. operates as a development-stage biomedical company. Curative Biotechnology, Inc. was founded in 1995 and is headquartered in Boca Raton, Florida. Curative Biotechnology operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 4 people. Curative Biotechnology (CUBT) is traded on NYSE MKT Exchange in USA and employs 4 people. Curative Biotechnology is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Return On Equity-3.98
Return On Asset-0.52

Curative Biotechnology Leadership Team

Elected by the shareholders, the Curative Biotechnology's board of directors comprises two types of representatives: Curative Biotechnology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Curative. The board's role is to monitor Curative Biotechnology's management team and ensure that shareholders' interests are well served. Curative Biotechnology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Curative Biotechnology's outside directors are responsible for providing unbiased perspectives on the board's policies.
Paul Michaels, President Chairman
BS BA, Vice Officer
Pam Bisikirski, Vice Communications
JD Esq, CFO, CEO
Ronald Bordens, Executive Board

Curative Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Curative Biotechnology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-3.98
Return On Asset-0.52
Current Valuation14.64 M
Shares Outstanding903.26 M
Shares Owned By Insiders0.05 %
Price To Sales158.53 X
Revenue132.32 K
Gross Profit100.21 K
EBITDA(2.5 M)
Net Income(3.96 M)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Curative Stock Analysis

When running Curative Biotechnology's price analysis, check to measure Curative Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Curative Biotechnology is operating at the current time. Most of Curative Biotechnology's value examination focuses on studying past and present price action to predict the probability of Curative Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Curative Biotechnology's price. Additionally, you may evaluate how the addition of Curative Biotechnology to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY